Bezuclastinib
Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM) [1].
Product Specifications
CAS Number
[1616385-51-3]
Product Name Alternative
CGT9486; PLX 9486
UNSPSC
12352005
Target
C-Kit
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bezuclastinib.html
Purity
98.81
Solubility
DMSO : 80 mg/mL (ultrasonic)
Smiles
O=C(C1=NNC(C)=C1C)NC2=CN=C3NC(C4=CC=CC=C4)=CC3=C2
Molecular Formula
C19H17N5O
Molecular Weight
331.37
References & Citations
[1]Guarnieri A, et al. Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Blood. 2021, 138: 4595. |[2]Guarnieri A, et al. Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration. MOLECULAR CANCER THERAPEUTICS. 2021, 20 (12) .
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
